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Summary One of the major discoveries of effective therapeutics is the use of targeted treatment, such as antibody-directed toxins, i.e.
immunotoxins; however, this medicine delivery strategy is still at a developmental stage. A number of problems need to be resolved; one is
their inefficacy when applied in vivo. Research has stimulated interest in this area through the use of chemical reagents and other moieties to
increase the activity of immunotoxins. In this article, reagents that can potentiate the cytotoxicity of immunotoxins are reviewed and the
mechanisms that increase activity of immunotoxins are discussed. Lysosomotropic amines, especially ammonium chloride and chloroquine,
may raise the pH value ofthe lysosome in which the conjugates enter. Carboxylic ionophores, e.g. monensin, can influence Golgi vacuolation,
which may facilitate the routing of conjugates, augmenting activity. Calcium channel antagonists may increase immunotoxin killing through
morphological or other mechanisms that are not yet well understood. Viral particles and surface structure can enhance the cytotoxicity of
conjugates, probably through the mechanism of disrupting endosomes. In addition, cytokines, 3-adrenergic blockers, immunosuppressive
agents (cyclosporin A) and some antibiotics (daunorubicin) can be used to increase the effect of immunotoxins.
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An immunotoxin (IT) (also called immunoconjugate) is achimeric
molecule, comprising a toxin and a monoclonal antibody (MAb),
designed to kill target cells in a highly efficient manner (Thrush et
al, 1996). Toxins (plant and bacterial toxins) are used as the cyto-
toxic part ofITs. MAbs are the most common delivery vehicles for
ITs, although growth factors, lymphokines and some antigens can
also be used as delivery vehicles. The most commonly used toxin
for ITs is ricin because ofits strong cytotoxicity and low immuno-
genicity to humans. Ricin is composed of two chains, A and B,
linked by a disulphide bond. The ricin toxin A-chain (RTA) is the
active part of the toxin which depurinates an adenine at position
4324 of the 28S rRNA of the large 60S ribosomal subunit and
results in the inhibition ofprotein synthesis, eventually leading to
cell death (Endo et al, 1987). The B-chain ofricin is not cytotoxic
but is able to bind to cell membranes through its (ga)lactose recep-
tors and translocates the ricin A-chain to the cell cytosol. IT conju-
gated with holotoxin ricin is much more cytotoxic than the
counterpart made of RTA; however, the non-specificity is more
apparent. Using RTA to make ITs is preferable for in vivo admin-
istration.
It is believed that a single ricin molecule can kill a cell when
it enters the cytosol; thus it was expected that ITs should be
highly potent for the killing target cells. In vivo or clinical studies
have shown that the effects of ITs, however, are not very satis-
factory. Numerous obstacles to the successful delivery of toxins,
via ITs, from the blood to the target cells, may affect the activity.
These include dissociation of cross-links, clearance from the
reticuloendothelial macrophage system, degradation in lysosomes
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by the enzymes, inability to access solid tumours, host immune
responses against the antibodies and toxins, and non-specificity
from the cross-reactivity of the monoclonal antibodies (Wu et al,
1993; Vallera DA, 1994). Numerous research groups are involved
in studies on overcoming the above problems. One of the most
important research areas is to improve the activity of ITs using
chemical reagents orbiological molecules, forexample ammonium
chloride orviral proteins. Here, the recentdevelopments in methods
used to enhance the cytotoxicity ofITs are reviewed (Table).
LYSOSOMOTROPIC AMINES
One of the greatest problems affecting the efficacy of ITs is the
degradation of drugs by lysosomal enzymes. Receptor-mediated
endocytosis is supposed to be the route of internalization of ITs.
This is characterized by a ligand binding to cell-surface receptors,
the clustering of receptor-bound ligands into coated pits on the
plasma membrane and the formation of uncoated vesicles called
'receptosomes' (FitzGerald et al, 1983), namely endosomes. After
processes involving the trans-Golgi apparatus, the endosomes and
the macromolecules will be delivered into lysosomes. In the lyso-
somes, the majority of the ITs may be destroyed by the enzymes,
and only those released from the lysosomes can be effective in
inhibiting protein synthesis. Lysosomotropic amines, such as
ammoniumchloride andchloroquine, can target the lysosomes and
result in the release ofmore ITs to the cytoplasm by increasing the
interior pH.
Ammonium chloride
Ammonium chloride is the most extensively studied reagent for
enhancing the activity of ITs. Previous kinetic studies of ITs
containing ricin showed that the rate ofprotein synthesis decreases
according to a monoexponential function, indicating a first-order
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process (Casellas et al, 1984). With increasing concentration ofthe
IT, a maximum rate of inhibition could be reached. The inactiva-
tion induced by the IT is much slower than that obtained with ricin
alone. The time required to reduce protein synthesis by 90%,
denoted T lo, is 1.4-1.6 h with ricin, but 60 h with anti-T65 IT on
T65-positive CEM human T cells. Ammonium chloride strongly
increases the rate of protein synthesis inhibition by ITs and
increases the sensitivity of cells to the IT. Raising the pH value of
the lysosomes in which the ITs have been taken up is thought to be
one mechanism of increasing cytotoxicity (Poole and Ohkuma,
1981). Casellas et al (1988) found that ammonium chloride could
increase the cytotoxicity of ITs only when the pH was raised to
above 7. This pH sensitivity of IT activation is an all-or-nothing
effect within an extremely narrow pH window of0.7 pH units. The
pH threshold required for an optimal effect is 8.1. Activation by
ammonium chloride is abolished by lowering the pH, which in
turn lowers the free ammonium content (NH3) ofthe medium. This
suggests that NH3 is the effective component in the activation of
ITs, while the protonated species, NH4+, has no effect. Only the
lipophilic form, the free NH3, can diffuse across the plasma and
lysosomal membranes so as to increase the cytotoxicity. F(ab')2 or
Fab IT are more effective than the whole IgG counterpart, and
their activity can be increased when applied with ammonium chlo-
ride. We found that ammonium chloride can enhance the cytotox-
icity of the ricin-HB55 (specific for MHC class II antigen)
eight-fold at 10 mm concentration (Wu et al, 1990). The range of
the potency of ammonium chloride for enhancing the IT activity
varies from eight- to 6700-fold, depending on conjugates as well
as targeted cells. Besides the possible in vivo application, ITs have
been used to treat leukaemia through in vitro purging of tumour
cells from the bone marrow before reimplanting into patients.
Ammonium chloride is not suitable for in vivo therapeutic usage,
but it may be useful for in vitro purging of bone marrow cells.
Chloroquine
Chloroquine has the advantage of being a clinical drug, which
might make it more suitable for the treatment ofpatients in combi-
nation with ITs. Chloroquine can enhance the cytotoxicity of ITs
by up to 2500-fold (Casellas et al, 1984) and has been shown to
increase the activity of expression of gene complexes delivered to
cells (Wagner et al, 1994). Akiyama et al (1985) investigated a
conjugate containing Pseudomonas exotoxin (PE) or epidermal
growth factor (EGF). The results did not reveal any apparent
activity for potentiating cytotoxicity after subtracting its intrinsic
toxicity, although it could increase intralysosomal pH. More
recently Marcil et al (1993) demonstrated that the activity of a
'hormonotoxin' (which contains gelonin coupled to the hormone),
lutropin, could be increased up to 10-15 times by quinacrine,
chloroquine, verapamil and monensin. Quinacrine and chloro-
quine are from the same family, but quinacrine was found to be
more effective than chloroquine in enhancing IT activity.
Other lysosomotropic amines
(P-glycylpheny1naphthylamide, methylamine,
amantadine)
Akiyama et al (1985) used ,3-glycylphenylnaphthylamide to
increase the cytotoxicity of an IT by coupling PE to anti-transferrin
antibody or EGF. The lysosomotropic agent has been tested at
20 gg ml-', resulting in an increase in IT cytotoxicity up to
20-fold. Poole and Ohkuma (1981) have shown that weakly basic
substances can increase intralysosomal pH in a concentration-
dependent manner. Methylamine is a weak base that influences
intralysosomal pH. A concentration of 10 mm could enhance the
activity of anti-T65 IT on CEM cells 13 300-fold (Casellas et al,
1984). Amantadine also is a potent enhancer of the cytotoxic
activity of anti-CD5-RTA IT against peripheral blood T cells. The
treatment of the IT resulted in a 100-fold reduction of the periph-
eral T cells; no adverse effects on the multipotential haematopoi-
etic progenitor cells were observed through the use of amantadine
(Siena et al, 1987). Another study demonstrated that amantadine
can potentiate cytotoxicity up to 1180-fold (Casellas et al, 1984).
Amantadine may be a better enhancer than ammonium chloride
because it is a licensed drug used for prophylaxis ofinfluenza. The
in vitro concentration used in the study (1 mmol 1-') might be diffi-
cult to achieve in the blood ofpatients; however, such a concentra-
tion may be used to purge malignant mature cells from the bone
marrow of leukaemia patients. This in vitro purging method is also
a useful tool in transplantation, after clearance of T cells, to
prevent or significantly reduce graph vs host disease. All the
lysosomotropic reagents may suit the designed purposes.
P-Glycylphenylnaphthylamide, amantadine and methylamine may
share the same mechanisms in enhancing the cytotoxicity of ITs,
namely by raising the pH value in lysosomes.
CARBOXYLIC IONOPHORES
Carboxylic ionophores, such as monensin, are well-studied
reagents for enhancing IT activity. Monensin, grisorixin and lasa-
locid enhance the effect of ricin ITs or RTA-ITs, but ionophores
such as nonactin, valinomycin and calcimycin have no effect on IT
cytotoxicity. Like lysosomotropic amines, carboxylic ionophores
inhibit the activity of ITs made of diphtheria toxin. The blocking
of the diphtheria toxin conjugates can only be observed when the
concentration of carboxylic ionophores is 20-fold higher than the
concentration for improving the cytotoxicity of ricin conjugates.
Moensin is an open-chain molecule that is capable ofion complex-
ation through a cyclic form stabilized by hydrogen bonding
between the carboxyl and hydroxyl groups (Mollenhauer et al,
1990). Carboxylic ionophores exchange monovalent cations
across membranes. Monensin, an Na+ ionophore capable of
collapsing Na+ and H+ gradients, may increase the pH of acidic
vesicles such as lysosomes through the exchange of Na+ for H+.
Monensin is a very effective potentiator that can function at a very
low concentration and can produce a significant increase in the
ricin A-chain IT with an ID50 in the picomolar or even less than
picomolar range. It is known that monensin can interfere with the
uptake of certain macromolecules. Jansen et al (1992) suggested
that monensin is approximately 105 times more potent than ammo-
nium chloride on a concentration basis. An increase in intralyso-
somal pH is also obtained with monensin, which thereby blocks
the lysosomal pathway of protein degradation. Roth et al (1988)
tested a conjugate of RTA and a MAb (45-2D9) against a glyco-
protein expressed by rat fibroblasts transformed with the Kirsten
sarcoma virus. These cells metastasize spontaneously and form
lung colonies in nu/nu and irradiated BALB/c mice. Intravenous
injection of the 45-2D9-RTA reduced the formation of the sponta-
neous pulmonary metastases and lung colonies originating from
freshly disaggregated tumour cells. Monensin potentiated the
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activity in vitro as well as in vivo, but ammonium chloride and
chloroquine could only potentiate it in vitro.
Potentiation of IT activity by monensin holds several advan-
tages: (a) monensin can be chemically cross-linked to carrier
proteins to increase solubility in vivo and to reduce the rate of its
clearance from body fluids; (b) unlike other reagents (e.g. ammo-
nium chloride) monensin action is not limited by intracellular or
extracellular pH and may also exert its function in the low pH
areas of a growing tumour mass; (c) monensin functions at very
low concentrations and is able to increase the cytotoxic action of
ITs made with vehicle molecules directed to different cell surface
structures.
Mechanisms of enhancing IT activity
Golgi vacuolization and the enhancement ofITactivity
Monensin has gained widespread acceptance as a biological and
biochemical investigative model to localize and identify the mol-
ecular pathways of subcellular vesicular traffic. The enhancement
of IT cytotoxicity by pharmacological reagents was found to be
correlated with vacuole formation and retention of the IT in
vacuoles by monensin, ammonium chloride or perhexiline.
Nevertheless, IT enhancement by monensin was much less effec-
tive in vivo in the mouse than would have been expected from in
vitro experiments. This phenomenon could be explained by inhibi-
tion ofmonensin activity in undiluted plasma in vitro. This inhibi-
tion of IT enhancement was paralleled by a disappearance of
vacuole formation around the Golgi apparatus, suggesting that this
underlining mechanism may be involved (Jansen et al, 1992).
It is not very clear how ricin enters cells. Receptor-mediated
endocytosis is the most widely accepted mechanism, but several
pieces of evidence suggest that the protein inside the cell is still a
heterodimer associated with coated or non-coated vesicles, endo-
somes, lysosomes and the Golgi apparatus, until the A-chain sepa-
rates from the B-chain and enters the cytoplasm. Lendaro et al
(1994) found that ricin could accumulate in the Golgi apparatus
and did not split the A-B heterodimer during translocation of the
toxin to the Golgi. This led them to believe that further processing
of ricin takes place in the cellular compartment. Wu et al (1994)
discovered that retinoic acid can increase the RTA-IT cytotoxicity
through the Golgi apparatus en route to the cytoplasm. As
brefeldin A (BFA) can block this potentiation by retinoic acid, it
induces a rapid dissociation of various coat proteins from the
membranes of the Golgi apparatus and the trans-Golgi network in
most mammalian cells (Uhlin-hansen and Yanagishita, 1995).
The use of a MAb against manosidase II, a Golgi apparatus
marker enzyme, demonstrated that the Golgi changes upon the
treatment with retinoic acid from a perinuclear network to a
diffuse aggregate. Electron microscopy of retinoic acid-treated
cells demonstrated the specific absence of any normal-looking
Golgi apparatus and a perinuclear vacuolar structure very similar
to that seen in monensin-treated cells.
Inhibition ofmonensin byhuman plasma
A serum glycoprotein (sGP) with an unexpectedly low pl ofabout
3.5 (sGP3.5) and a molecular mass ofabout 45 kDa was shown to
be responsible for plasma inhibition of monensin enhancement of
ITs; possible mechanisms for this process are considered below
which may lead to an explanation of how monensin functions:
(1) sGP3.5 may act on an upstream mechanism common to the
activities of monensin and perhexiline (a calcium channel antag-
onist that will be discussed later); (2) simultaneous inhibition ofIT
enhancement and ofmorphological alterations aroundthe Golgi by
the same sGP, indicating a correlation between these two
processes; and (3) sGP3.5 may be involved in the physiological
regulation ofintracellular trafficking.
Human serum albumin-monensin conjugate
Jansen et al (1987) indicated that the use of the conjugate of
monensin and human serum albumin (HSA-Mon) in combination
with anti-human T-cell IT could increase the survival of athymic
mice bearing human T-cell leukaemia. Another study on a conju-
gate of linoleate and monensin was also shown to potentiate anti-
mesothelioma conjugates in a nude mouse model (Griffin et al
1991). Colombatti et al (1990) evaluated the ability of HSA-Mon
to facilitate the in vitro cytotoxicity of several ITs that target
different cell lines. The conjugate form is 2- to 13-fold less toxic
than native monensin in vitro but was active in the same concen-
tration range as monensin in potentiating MAb-RTA and
Tfn-toxin conjugates reactive with Tfn receptors expressed by
different cell lines in monolayer cell cultures. To test the cytotoxic
potential of the IT against non-vascularized micrometastases,
Colombatti's group developed a quantitative assay based on
limiting dilution analysis of spheroid cells surviving after treat-
ment with IT and monensin or HSA-Mon. Multicell tumour
spheroid cultures were used to investigate the cytotoxicity in
three-dimensional structures by mimicking the properties of non-
vascularized micrometastases. Spheroids (300-400 im) were
as sensitive to Tfn-RTA and HSA-Mon in combination as
monolayer cells.
The study of stability of HSA-Mon in human serum and cere-
brospinal fluid showed that 2% HSA-Mon remained available for
potentiation after a 24-h incubation at 37°C and about 10% in
human cerebrospinal fluid. The half-life of the conjugate in the
serum of BALB/c mice was 30 min. These results suggest that
HSA-Mon may be a good candidate as a potentiator of anti-
tumour cytotoxic heteroconjugates in vivo, especially when a
regional IT administration is contemplated.
Monensin-MAb-containing small unilamellar vesicles
(liposomes)
Griffin et al (1993) revealed that ITs can be potentiated with
monensin-liposome conjugates made by the French press method.
As these conjugates were not very homogeneous, Singh et al
(1994) attempted an approach to enhance RTA-IT by monensin
containing small unilamellar vesicles. In this experiment,
monensin was entrapped in small unilamellar vesicles made by the
extruder method. Monensin-liposomes were prepared with the
lipid composition DPPC/CHOL/SA/PDP-SA (5:3:1:1) using the
hydration method (Mezei and Nugent, 1984). The liposomes were
then extruded through various polycarbonate membranes of
decreasing pore size, 0.4 jm, 0.2 jm, 0.1jIm and 0.05 ,um, using
the high-pressure extruder device. The monensin-liposomes of
diameter 100-150 nm were more potent than the monensin-
liposomes of diameter 2 500 nm. The monensin-liposomes
were further conjugated to a MAb with specific tumour reactivity.
The MAb-targeted monensin-liposomes potentiated the IT cyto-
toxicity by 100-fold compared with the non-MAb-targeted
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monensin-liposomes and were also much better than monensin
alone. It was shown to have no in vivo toxicity in SCID mice atthe
concentration 10-6 M when the monensin-liposomes were intra-
venously injected.
Above, the research on monensin, including the mechanisms,
has been described. Overall, monensin has the potential to assist
the use of ITs and can increase the activity of ITs -50 000 times
(Casellas et al, 1984). Monensin has some disadvantages,
however, such as general toxicity and unfavourable pharmaco-
kinetics, which may hamper the in vivo application. It is worth
studying the clinical effect when monensin is applied in combina-
tion with ITs.
ANTAGONIST OF CALCIUM CHANNEL
Calcium channel blockers and their derivatives have been studied
with a view to improving macromolecule cytotoxicity. They can
provide up to 100-fold increase of IT efficacy. The mechanisms
appear to be not associated with the calcium channel but are prob-
ably related to the prevention of the lysosomal degradation of the
IT conjugates.
Verapamil and its derivatives
Verapamil (a calcium channel blocker) was shown to enhance the
cytotoxicity of both PE-ITs and RTA-ITs containing EGF up to
40-fold (Akiyama et al, 1984). In this study, another two calcium
channel blockers were tested. Diltiazem enhanced the cytotoxicity
of EGF-PE, but nitedipine did not. It might be difficult to use vera-
pamil in vivo, because the concentrations needed for in vitro
enhancement were in the range of 2-20,ug ml-'. These concentra-
tions are difficult to achieve and maintain in the serum of patients
without cardiac toxicity. Pirker et al (1989) studied the enhance-
ment of the activity of ITs by analogues of verapamil, CD792
(amidosulphonate), D595 (hydrochloride), D528 (dihydrochloride)
and Sz45 (hydrochloride). Each ofthe four analogues enhanced the
activity of RTA-IT in a dose-dependent manner. D595 and D792
also increased ITs containing PE (HB21-PE), but high concentra-
tions ofthese two analogues either had less enhancing potency than
low concentrations or even decreased the activity of HB21-PE.
Specific enhancement by the analogues was demonstrated by
competing the IT activity against the corresponding antibody, and
the verapamil analogues could not influence the activity of an irrel-
ative conjugate that is not directed to the target cells. The range of
enhancement was from twofold to more than 60-fold and depen-
dent on cell lines or the experimental conditions.
The enhancement activity is not related to the calcium antag-
onist activity with regard to both ricin A IT and PE IT. Verapamil
and the analogues could delay lysosomal degradation of the ITs,
thereby enhancing the ITs' activity. Verapamil was found to
enhance accumulation in the lysosomes, whose activity may be
accounted for by verapamil analogues increasing membrane
permeability. Verapamil may alter cellular membranes in a manner
that independently affects the translocation of ITs and lysosomal
function (Akiyama et al, 1984). The drugs could also affect the
activity of ITs in more than one way. Sz45 and D528 might inhibit
lysosomal degradation, but at high concentration Sz45 and D528
increase endosomal or lysosomal pH. Such an increase in pH
would decrease the activity of HB21-PE, because PE needs an
acidic environment for cell killing.
Perhexiline
Perhexiline maleate is another calcium channel antagonist and
is able to enhance IT cytotoxicity. Jaffrezou et al (1990) revealed
that perhexiline could significantly enhance the cytotoxicity of
the IT containing an anti-CD5 MAb and RTA in both cultured
cell lines and fresh chronic leukaemia cells but ammonium chlo-
ride, monensin and verapamil could not increase the cytotoxicity
of the IT. Therefore, this increase in sensitivity to RTA-IT is a
result of alterations in events that occur during the intemalized
degradation of RTA-ITs and may be caused by changes in
membrane lipid constitution. Perhexiline has a greater enhance-
ment effect than some other calcium antagonists, e.g. verapamil,
and it also acts at much lower concentration. The calcium channel
is not involved in the mechanisms as, in the presence of either
ethylene glycol bis (2-aminoethyl ether)-N,N,N'N'-tetraacetic
acid or cobalt, the activity is not changed. Perhexiline reduces
gold-labelled RTA-IT in lysosomes and increases the number
of tubulovesicles, which suggests that perhexiline induces
changes in intracellular routing, whereas ammonium chloride
may increase the size of lysosomes and monensin may cause
vacuolization of the Golgi, perturbing RTA-IT routing in this
region. The common result of these three agents is a decrease in
RTA-IT accumulation in secondary lysosomes and an increase in
the finely structured tubulovesicles. Electron microscopy obser-
vations suggested that alteration of fusion process between endo-
cytic vacuoles and lysosomes occurred in perhexiline-treated
cells.
Only perhexiline, and ammonium chloride, not verapamil,
monensin and perhexiline analogues, could induce lysosomal
phospholipidosis in treated cells. These morphological alterations
were related to the inhibition by an amphiphilic cationic drug
perhexiline - an acid sphingomyelinase inhibitor. Inhibition of
sphingomyelinase (hydrolysed sphingomyelin) is dose dependent
and correlates with its IT enhancement activity. Interestingly, long
incubation with gentamycin, a non-amphiphilic lipodosis-inducing
aminoglycoside (a potent acid sphingomyelinase inhibitor), also
significantly enhanced HNC-241 RTA-IT cytotoxicity against Raji
cells. Sphingomyelinase-deficient cell lines were not sensitive to
the enhancement by perhexiline. Taken together, these observa-
tions suggest that perhexiline may act by disturbing membrane
lipid composition through its inhibiting action on acid sphin-
gomyelinases, leading to modifications in intracellular routing and
to subsequent degradation of these RTA-ITs.
The implication from these findings is that the choice of
enhancing agents will depend on both the choice of ITs and
targeted tumour cell populations. Thus, other sphingomyelinase
inhibitors could possibly be chosen to enhance IT activity.
Another possible mechanism of perhexiline activity is vacuole
formation, which is one of the ways in which monensin enhances
IT activity and is again related to the pH increase. This requires
very high concentrations of up to 5 ,UM to increase the pH to 6.0,
but perhexiline works at only 5.0 nm (100 times less). Monensin
considerably delays intracellular trafficking to lysosomes by
retaining IT in the newly formed large intracellular vesicles. The
perhexiline-induced inhibition of ITs also correlates with morpho-
logical alterations. ITs are retained in a similar way in intracellular
vesicles before reaching lysosomes.
The perhexiline enhancement activity could be inhibited by
cytoplasms, and the mechanisms have been discussed above in the
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last section concerning the cytoplasm inhibition of enhancing IT
activity by monensin (Jansen et al, 1992). Taken together, perhexi-
line may enhance ITs through more than one mechanism.
VIRUSES AND VIRAL PARTICLES
Viruses use specialized envelope structures that allow them to enter
the cytosol ofthe infected cells. The normal endosomal acidification
process specifically activates viral coat protein domains of
membrane-free viruses, such as adenoviruses; this triggers the
disruption of the endosomal membrane. Enveloped viruses, such as
influenza viruses, fuse the viral envelope to the endosomal
membrane before infection. The viral entry functions have been
found to influence the intracellular delivery of other molecules.
Several groups have observed that the presence of adenoviruses
during receptor-mediated endocytosis ofmacromolecules (PE conju-
gated to EGF receptor or Tfn receptor) enhances the entry of the
macromolecules into the cell cytoplasm. Receptor-mediated entry is
analogous to virus entry, in which the complexes are coated with Tfn
as a ligand for attachment to the cell and then the nucleic acid
genome with core protein is condensed with it. This phenomenon is
common to adenoviruses, influenza viruses and the picomaviruses.
The study of the membrane disruption and fusion procedures
that occur during viral entry and other important biological
membrane events has led to the identification of amphipathic
a-helical peptide sequences that are responsible for these
membrane processes. The influenza virus haemagglutinin struc-
ture is particularly well studied. The N-terminus of the subunit
HA-2 contains a membrane-active peptide sequence which, at
neutral pH, because of charge repulsions between negatively
charged amino acid side-chains, prevents carboxylate groups from
adopting an a-helical conformation. Upon lowering the pH to
< 6.0 these charges are neutralized by protonation, allowing a tran-
sition to an a-helical amphipathic structure and enabling the inter-
action and destabilization of lipid membranes in the natural
context of facilitating the fusion of viral and endosomal
membrane. Thus HA-2 peptide can be used to enhance the cyto-
toxicity ofITs by facilitating their entry into target cells.
Chignola et al (1995) modified RTAbyfusing it to aprotein struc-
ture derived from viral envelope, thus conferring the cytosol-
targeting properties ofthe virus onto the cytotoxic enzyme-modified
RTA. A peptide representing the primary sequence of the
25 N-terminal amino acid of protein G of the vesicular stomatitis
virus envelope (KFT25) was found to have pH-dependent
membrane-destabilizing properties. Chimeric RTA retained the
enzymatic activity in a cell-free assay but was 10-fold less toxic
against human leukaemia cell lines than native RTA. However, Tfn
conjugated with cloned RTA (cRTA) is 10- to 20-fold more cyto-
toxic than Tfn and natural RTA (nRTA). These results suggested that
the ability ofvesicular stomatitis virus protein G to interact with cell
membranes facilitate the translocation ofRTA to the cell cytosol.
The mechanisms of facilitating conjugate cytotoxicity by
viruses are not completely elucidated due, it has been proposed, to
the fusogenic activity by the viral peptide. The acidification of
these endosomes by an ATP-dependent proton pump is responsible
for initiating the fusion ofviral and cellular membranes (Eidelman
et al, 1984; Florkiewicz and Rose, 1984). Recently, computer
simulations of the structure of KFT25 and calculations of the
hydropathicity and ofthe mean hydrophobic moment ofthe KFT25
peptide indicated that the peptide is composed of three distinct
structural regions separated by Pro residues: an N-terminal
hydrophobic a-helix (Lys-Pro region), a central hydrophilic glob-
ular structure (His-Pro region) and a slightly hydrophilic
C-terminal 5-structure (Ser-Pro). The N-terminus can potentially
span the first layer ofthe plasma membrane at pH 7.0 with an emis-
sion of 5.3 kcal mol-'. This calculation supports the data reported
by Schlegel and Wade (1985) that the first six amino acids of
KFT25 are haemolytic even at physiological pH, whereas the glob-
ular region would be implicated in the pH activation of the
haemolytic properties of the entire peptide. The properties of the
KFT25 peptide could explain the lower cytotoxic activity ofuncon-
jugated cRTA. cRTA might insert into the plasma membrane and
may remain entrapped within the lipid layers as a consequence.
Unconjugated cRTA has lower translocation potential as compared
with nRTA, but once cRTA is vehicled near the membrane by Tfn,
cRTA can insert itselfinto the lipid layer. Upon acidification ofthe
environment, cRTA would increase its N-terminal positive charge
because ofthe His residues. This would lead to a disorganization of
the bilayer structure as a result of attracting the negative charges
present on the cytosolic surface of the cellular membranes. The
disorganization would facilitate the translocation of the cRTA to
cell cytosol. A role in the pH activation of the KFT25 properties
could also be played by the proline residues.
Adenovirus
The capacity of adenovirus to disrupt endosomes as part of their
entry mechanisms was exploited to enhance the efficiency of gene
delivery and cytotoxic conjugates (FitzGerald et al, 1983; Curiel et
al, 1991; Wu et al, in preparation). Using electron microscopy,
FitzGerald et al (1983) first reported that adenovirus can help
release EGF-gold conjugates from the receptosomes into the
cytosol. Adenovirus enhanced the toxicity of PE by 100-fold and
the cytotoxicity of the IT, consisting of PE-EGF, by 10 000-fold
through disruption of receptosomes. Adenovirus infection
augmented levels of gene transfer by transferrin-polylysine
conjugates in a dose-dependent manner: levels of gene transfer
of >2000-fold were achieved. Adenovirus enhances levels of
gene transfer in a variety of targeting cells, including cell lines
otherwise refractory to gene transfer by transferrin-polylysine
conjugates. The augmentation was based on adenovirus-mediated
vesicle disruption, a process independent of viral gene expression.
The inhibiting factors for gene transfer were thought to be a
consequence of lysosomal targeting of the endosome-intermalized
conjugate-DNA complexes (Wagner et al, 1994). Agents to inhibit
lysosomal enzymes have been used to increase the fraction of
DNA that would escape degradation and be expressed within the
nucleus. The development of specific mechanisms to effect release
from the endosome in combination with gene transfer by the
receptor-mediated endocytosis pathway will increase the use of
this delivery system by allowing high levels of gene expression in
target cells. We also found that adenovirus can increase the cytotox-
icity of RTA delivered by bacteriophage MS2 capsids (Wu et al,
1995; in preparation).
CYTOKINES
O'Boyle et al (1995) reported a conjugate of gelonin and MAb
(lym-1) - class II HLA-DR antigen. In vitro cytotoxicity of the
conjugate was confirmed by the delivery ofMAb lym-L. y-interferon
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(IFN) augmented the antiproliferative effects of lym-1-gelonin
conjugate, especially at its low concentration and unconjugated
lym-1. Tumour necrosis factor alpha (TNF-a) also enhanced the
antiproliferative activity of free lym-1 but did not significantly
increase thecytotoxicity ofthe conjugate. The augmentation ofthe
conjugate may be due to an additive cytotoxicity effect because
y-IFN exhibited some direct cytotoxic activity on Raji lymphoma
cells (expressing class II antigen) in the absence of the conjugate.
This combined therapy that has an augmented effect may be useful
means of treating tumours. It is considered that y-IFN retards the
growth and proliferation of both tumour and normal cells through
elongating the cell cycle. y-IFN works through a signal transduc-
tion mechanism by inducing phosphorylation of protein kinase
JakI and Jak2 as well as y-IFN receptor. The ability ofy-IFN, and
to a lesser degree TNF-o, to significantly enhance the antiprolifer-
ative effect of conjugated lym-1 is also remarkable. This suggests
some type of synergistic interaction between the cytostatic effects
of a growth-regulatory MAb and cytotoxic activity of cytokine,
especially y-IFN which could kill the more slowly growing malig-
nant B cells better than before. The mechanism is probably as a
result of activation of kinases and phosphorylated proteins that
slow down tumour cell growth and cause the cells to undergo
apoptosis. The TNF-ax mechanism in vitro is thought to be
different from its mechanism in vivo. The haemorrhagic necrosis
seen in vivo is the result of its effects on tumour endothelium,
generating procoagulant activity and decreased perfusion of the
tumour. TNF-ax needs to be internalized for its in vitro activity,
because chloroquine and colchicine, which disrupt the endocytic
process, inhibit its effects. TNF-a participates in the signal
transduction pathway by stimulating PKC activity. TNF-ax and
y-IFN can also have a synergistic cytotoxic effect on haemato-
poietic progenitor cells and can induce expression ofthe apoptosis-
associated antigen (FAS or CD95).
Yokota et al (1990) investigated the in vivo effect of recombi-
nant human a-IFN on the anti-tumour activity of ITs containing
RTA and anti-human leukaemia MAb SNl or SN2. SN1 and SN2
are directed towards two unique T-leukaemia-associated antigens,
TALLA and GP37 (Yokoda et al, 1993). Nude mice were inocu-
lated with Ichikawa cells and treated for 4 days with ITs plus a-
IFN. The results showed 100% inhibition of tumour growth in the
treated mice, while similar treatment with each agent alone was
only partly effective. The results indicated that IFN potentiates the
in vivo anti-tumour activity ofthe ITs, primarily by host-mediated
effector mechanisms but not by direct action of IFN-a on the
leukaemia cells. The activation of macrophages by IFN in the
tumour-bearing nude mice appears to be the major factor in the
potentiation of the in vitro anti-tumour activity of the ITs in this
study. IFN exerts a variety ofeffects on tumour cells at the cellular
level. These effects can be divided into two groups, i.e. effects by
the direct action of IFN on the tumour cells and the host-mediated
effects. IFN potentiated both NK cells and macrophage activity in
the tumour-bearing nude mice. Ishikawa leukaemia cells are resis-
tant to NK cell lysis, therefore macrophage activation by IFN
appears to be the major factor in the synergistic potentiation of
anti-leukaemia activity ofthe ITs. The results have been supported
by Basham et al (1988) and Cameron et al (1988) who demon-
strated that the host effector mechanisms were important in poten-
tiating anti-tumouractivity ofanti-idiotype antibody or interleukin
2 (IL-2) by hIFN-ax.
Pearson et al (1993) discovered that hIFN-a can potentiate the
activity ofan IT against ovarian carcinoma cells and this is depen-
dent on tumour burden. These agents are less effective against
large tumour burdens but their beneficial effects re-emerge after
cytoreduction by a combination of chemotherapy with conven-
tional chemical drugs (CDM, CDDP). It is important to note that
rhIFN-ax is species specific (Pearson et al, 1990). These data
showing the use ofIFN for enhancing ITs provides an idea that the
combined therapy of ITs and cytokines may be promising for the
treatment ofdiseases, including tumours and AIDS.
3-ADRENERGIC BLOCKING AGENTS
IT in vivo activity is often diminished by their ability to gain
access to the tumour site in appropriate concentrations. Another
problem for ITs is their difficulty in gaining access to tumours via
the endothelial and reticuloendothelial barriers. The accessibility
of solid tumours by ITs is even worse because of their dense
connective tissue and relatively restricted blood supply. Changes
in blood flow in and around tumour masses could significantly
alter the effectiveness of therapies, and vasoactive drugs can be
used to alter the distribution of blood flow between tumour and
normal tissues when using ITs. It was found that non-selective and
cardioselective 3-adrenergic blocking agents could increase three-
fold tumour-to-blood and tumour-to-liver perfusion of1251-labelled
MAbs (Smyth et al, 1987). These P-adrenergic blockers increased
the anti-tumour efficacy of idarubicin (Ida)-MAb conjugates.
These agents in combination with the conjugates produced a
smaller mean tumour size and a greaternumberofregressions than
the conjugate-alone groups in the tumour-bearing mice, but
prazosin hydrochloride (a,-adrenergic blocking agent) and
Cyclosasmol (peripheral vasodilator) could not enhance the tumour
perfusion and anti-tumour efficacy of '25I- or Ida-conjugated
MAbs. It was demonstrated that the 32-adrenergic blocking effect
is not related to this enhancing ability. These results might suggest
that ,B-adrenergic blocking agents are useful in tumour therapy in
combination with immunoconjugates.
The studies of f2-adrenergic blockers were only limited in the
MAb-radioisotope conjugates and its role for enhancing
MAb-toxin conjugates has not been reported. Investigation is
required on the possible potence of V2-adrenergic blockers in
targeted therapy.
CYCLOSPORIN A, DAUNORUBICIN AND
RETINOID ACID
Cyclosporin A
It is difficult to eradicate virtually all neoplastic cells in a hetero-
geneous population of cells that have the capacity for continuing
genetic alteration. Prevention ofcancers has been recently empha-
sized as a more effective means for cancer control. Cyclosporin A
is an immunosuppressive cyclic peptide widely used to prevent
rejection of allogeneic grafts. Yefemof et al (1992) discussed an
issue ofusing cyclosporin A to potentiate the IT activity oftumour
prevention. Cyclosporin A is able to inhibit lymphokine secretion
by T cells. The investigators constructed an IT containing degly-
cosylated RTA (dgA) and a MAb (2F10) against the radiation
leukaemia virus (RadLV) envelope glycoprotein (gp7O). RadLV is
a retrovirus that induces clonal thymic lymphomas in C57BL/6
mice after alatency period of3-6 months. Apleioclonal population
of preleukaemic (PL) cells is not malignant but can progress to
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Table Enhancement of IT activity by various reagents
Reagents Enhancement (fold) Immunotoxins Reference
Ammonium chloride 10-1625 Anti-T65-RTA, anti-Thy 1.2, Casellas et al (1984)
anti-T101-RTA Casellas et al (1988)
3-Glycylphenylnapht- 10 Anti-Tfn-PE Akiyama et al (1985)
hylamide Epidermal growth factor-PE
Methylamine 50% more inhibition than IT alone Anti-T101-RTA Siena et al (1987)
Poole and Ohkuma (1981)
Amantadine 98% more inhibition than IT alone Anti-T11-RTA Siena et al (1987)
Chloroquine 10-15 Lutropin-gelonin Marcil et al (1993)
Monensin 42-420 RTA-IT Singh et al (1994)
Perhexiline 10-2000 Anti-CD5-RTA, Gaffrezou etal (1990)
T101, Tl01 F(ab)2
Verapamil 2-60 RTA-anti-Tfn receptor HB21-PE Pirker et al (1989)
Viral peptide 10-20 Tfn-RTA-KFT viral peptide Chignola et al (1995)
Adenoviruses - 10 000 PE-EGF FitzGerald et al (1983)
> 2000 gene transfer efficiency Tfn-polylysine-DNA complex Curiel et al (1991)
Interferons 100% inhibition of tumour growth Anti-T leukaemia Ab-RTA Yokota et al (1990)
,-Adrenergic blockers threefold tumour to I-labelled MAb Smyth et al (1987)
blood perfusion conjugates
Cyclosporin A 100 Anti-CD5-RTA Jeffrezou et al (1994)
Eradication of Anti-RadLV-dgRTA Yefernof et al (1992)
RadLV-infected cells
Daunorubicin 80% inhibition of Anti-T leukaemia Ab-RTA Yokota et al (1990)
tumour growth
Retinoic acid > 10 000 Anti-Tfn Ab Wu et al (1994)
454A12-RTA
Ricin B-chain From non-effect to effect RTA-IT Mcintosh et al (1983)
B-chain IT (same Ab in RTA-IT) Several folds RTA-IT to neoplastic B cells Vitetta et al (1983)
Piggyback B-chain IT Several folds RTA-IT to neoplastic B cells Vitetta et al (1984)
KDEL peptide Markedly PE-ITs Chaudhary et al (1990)
KDEL peptide Significantly RTA Wales et al (1993)
lymphoma. Long-term existence of the PL cells after inoculating
thymus has been attributed to the ability ofthe virus to induce both
interleukin 4 (IL-4) and IL-4 receptor expression. The IT 2F10-
dgA eradicated the host majority of RadLV-infected cells. This
treatment delayed the premalignant process as the few surviving
PL cells are still capable of progressing into malignant lymphoma.
With the administration of the IT plus cyclosporin, the escaping
PL cells were eliminated through blocking the IL-4 secretion. The
mechanisms are not clear, but one ofthe profound biological activ-
ities is the inhibition of lymphokine production and secretion in
activated T cells. This terminates malignant development.
Jaffrezou et al (1994) evaluated the ability of cyclosporin A and
its non-immunosuppressive analogue, SDZ PSC 833, to enhance
anti-CD5 RTA ITs in vitro. At 4 ,uM, both reagents increased the
cytotoxicity of the anti-CD5 IT on the human lymphoblastic T-cell
line CEM by 100 times. These reagents could also increase anti-
CD5 F(ab')2 RTA IT (a more potent IT) by 8-9 times. They did not
affect the rate ofRTA-IT binding, internalization, intracellular traf-
ficking or degradation. It was found that the internalized anti-CD5
IT were intact, which suggests that the enhancers may act only on
a small population of RTA IT that escapes present investigational
techniques. The study of the in vivo toxicity of cyclosporin A
demonstrated that a concentration of 4 ,uM in the body did not
result in long-term immunosuppressive consequences. The main
side-effect is capillary-leak syndrome (possibly related to
immunosuppressive activity) which could be treated by gluco-
conicoids. This indicates that the non-immunosuppressive
analogue SDZ PSC 833 is more appropriate in the clinical applica-
tion, because SDZ PSC 833
activity of Ils.
is more effective in enhancing the
Daunorubicin
Daunorubicin is an antibiotic of the rhodomycin group and is
being widely used for treating human leukaemias; daunorubicin
inhibits DNA and RNA synthesis in the cell. Daunorubicin kills
target cells by a different machanism from cytotoxic ITs. The inhi-
bition of nucleotide synthesis can lead to the inhibition of protein
synthesis as polynucleotides are necessary for protein synthesis. It
was shown that daunorubicin could facilitate the activity ofthe ITs
against human T-leukaemia-associated antigens (Yokota et al,
1990). In nude mice T-leukaemia models, daunorubicin plus ITs
suppressed the tumour growth up to 80%, which is similar to ITs
plus IFN, however ITs with IFN plus daunorubicin could result in
100% suppression of tumour growth. Thus the combined action of
daunorubicin and ITs could achieve additive cytotoxicity through
multiple mechanisms. Griffin et al (1989) also found that doxo-
rubicin, another chemotherapeutic agent, potentiated in vivo anti-
tumour activity of an anti-human transferrin receptor IT.
Retinoic acid
Retinoic acid can selectively increase the potency of some ITs (Wu
et al, 1994). Retinoic acid increases the activity of ITs with RTA
but does not increase the activity of ITs from diphtheria toxin and
PE. BFA can block retinoic acid-mediated IT potentiation but not
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monensin-mediated IT potentiation. This demonstrated that
retinoic acid possesses some characteristics of IT potentiation
similar to monensin, but some different from monensin. This indi-
cates that retinoic acid might be a new reagent to manipulate the
Golgi apparatus, but in vivo experiments are required to analyse
the ability to enhance the efficacy of ITs.
OTHERS
Introduction of KDEL peptide
The sequence Arg-Glu-Asp-Leu-Lys (REDLK) at the carboxyl
terminus of PE is known to be important for its cytotoxicity,
though it is not required for the binding and enzymic process. The
REDLK is strikingly similar to the endoplasmic reticulum
retrieval sequence KDEL (Chaudhary et al, 1990; Seetharam et al,
1991). During the intoxication process, PE is cleaved by an intra-
cellular protease between amino acids 279 and 280 to generate an
Mr 37 000 carboxyl terminal fragment that contains the ADP-ribo-
sylation activity. This fragment appears to be directed to the endo-
plasmic reticulum by the REDLK sequence at its carboxyl
terminus, from which compartment it translocates to the cytosol. If
REDLK is replaced by KDEL, the cytotoxic activity ofPE can be
increased. PE contains a KDEL-like C-terminal sequence that can
bind the KDEL-receptor in the Golgi that is proposed to carry PE
out of the Golgi to the endoplasmic reticulum for efficient trans-
port to the cytosol. A number of fusion proteins that contain PE
domain III with a KDEL peptide linked to various ligands,
including transforming growth factor a, EGF, Tfn, EGF-like
domain ofheregulins, IL-2, IL-4, IL-6, etc., have been studied (Pai
and Pastan, 1993; Gottstein et al, 1994; Thrush et al, 1996). The
cytotoxicity of all the fusion proteins are increased when the
carboxyl terminus is attached with a KDEL. Lord and his
colleagues (Wales et al, 1993) developed a series of fusion
proteins by replacing the KEDLP of ricin A-chain with a KDEL
sequence. A considerable increase in the cytotoxicity was also
achieved. The results in our laboratory also showed that RTA-
KDEL conjugates carried with MS2 bacteriophage coat protein
were more cytotoxic to the target cells (Wu et al, unpublished).
Thus the KDEL-derivatized conjugates hold stronger cytotoxicity,
and these ITs may be better agents than the conjugates containing
a native toxin for the therapeutic application.
Synergy of ricin B-chain and its ITs
We discussed in the opening section the role of ricin B-chain,
which is important for ITs although the B-chain is not required to
exert the protein synthesis inhibition. B-chain aids the transloca-
tion ofthe A-chain and probably protects the A-chain from degra-
dation. Therefore several strategies have been tried to increase the
RTA-IT activity with the B-chain. A direct approach is to add free
ricin B-chain after target cells have bound to RTA-ITs, as free B-
chain can bind to the A-chain ofITs more readily than they bind to
the galactose-containing glycoproteins on the cell surface. It was
found that the B-chain potentiated the toxicity of RTA-ITs in vitro
when the concentration of extraneous glycoproteins was low
(McIntosh et al, 1983). Use ofthe B-chain in vivo seems unlikely
because of the much higher concentration of glycoproteins and
cells bearing these glycoproteins in the blood. Thus free B-chain
will be diminished before reaching the target cells ofITs.
Vitetta et al (1983) pioneered the use of a B-chain IT to
improve an IT with RTA. The idea was that if both the ITs were
bound to the same cell, they would be endocytosed within the
same vesicle and cleaved from their IT, allowing the B-chain to
perform translocation of the A-chain. In vitro assays confirmed
that the B-chain IT potentiated the A-chain IT. Again by
Vitetta's group, the approach was extended by generating a
B-chain IT in which the antibody is reactive to the antibody of
the RTA-IT, namely 'piggyback' (Vitetta et al, 1984). This
experiment in the use of the B-chain IT for enhancement was
described as being successful. It is necessary to stress that these
strategies require highly purified ITs by affinity chromatog-
raphy or the free A- and B-chain will reform, resulting in non-
specific strong toxicity. There were no further developments in
the investigation, thus there may be problems in the pharma-
cology or methodology. The reagents for enhancing IT activity
are summarized in the table.
CONCLUSIONS
Treatment oftumours and some other refractory diseases are long-
term issues in which considerable progress has been achieved over
the last 20 years. However, the therapeutic strategies that are being
developed are not panacea and usually enjoy only partial success.
The treatment oftumours with ITs in combination with some other
drugs or chemical reagents, such as cytokines, amines, calcium
channel antagonists and carboxylic ionophores, can markedly
potentiate anti-tumour effect.
We propose here that the treatment of refractory diseases by
combined therapy may yet prove a means of controlling diseases.
The use of ITs together with enhancing reagents has potential, and
it is therefore worthwhile investigating its application.
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